Additive effects of booster mRNA vaccination and SARS-CoV-2 Omicron infection on T cell immunity across immunocompromised states.


Journal

Science translational medicine
ISSN: 1946-6242
Titre abrégé: Sci Transl Med
Pays: United States
ID NLM: 101505086

Informations de publication

Date de publication:
12 07 2023
Historique:
medline: 14 7 2023
pubmed: 12 7 2023
entrez: 12 7 2023
Statut: ppublish

Résumé

Suboptimal immunity to SARS-CoV-2 mRNA vaccination has frequently been observed in individuals with various immunodeficiencies. Given the increased antibody evasion properties of emerging SARS-CoV-2 subvariants, it is necessary to assess whether other components of adaptive immunity generate resilient and protective responses against infection. We assessed T cell responses in 279 individuals, covering five different immunodeficiencies and healthy controls, before and after booster mRNA vaccination, as well as after Omicron infection in a subset of patients. We observed robust and persistent Omicron-reactive T cell responses that increased markedly upon booster vaccination and correlated directly with antibody titers across all patient groups. Poor vaccination responsiveness in immunocompromised or elderly individuals was effectively counteracted by the administration of additional vaccine doses. Functionally, Omicron-reactive T cell responses exhibited a pronounced cytotoxic profile and signs of longevity, characterized by CD45RA

Identifiants

pubmed: 37437015
doi: 10.1126/scitranslmed.adg9452
doi:

Substances chimiques

RNA, Messenger 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

eadg9452

Auteurs

Thomas R Müller (TR)

Department of Medicine Huddinge, Center for Infectious Medicine, Karolinska Institutet, Stockholm, Sweden.

Takuya Sekine (T)

Department of Medicine Huddinge, Center for Infectious Medicine, Karolinska Institutet, Stockholm, Sweden.

Darya Trubach (D)

Department of Health Technology, Section of Experimental and Translational Immunology, Technical University of Denmark, Kongens Lyngby, Denmark.

Julia Niessl (J)

Department of Medicine Huddinge, Center for Infectious Medicine, Karolinska Institutet, Stockholm, Sweden.

Puran Chen (P)

Department of Medicine Huddinge, Center for Infectious Medicine, Karolinska Institutet, Stockholm, Sweden.

Peter Bergman (P)

Department of Infectious Diseases, Karolinska University Hospital, Stockholm, Sweden.
Department of Laboratory Medicine, Clinical Immunology, Karolinska Institutet, Stockholm, Sweden.
Department of Clinical Immunology and Transfusion Medicine, Karolinska University Hospital, Stockholm, Sweden.

Ola Blennow (O)

Department of Infectious Diseases, Karolinska University Hospital, Stockholm, Sweden.
Department of Transplantation, Karolinska University Hospital, Stockholm, Sweden.
Department of Medicine Huddinge, Infectious Diseases, Karolinska Institutet, Stockholm, Sweden.

Lotta Hansson (L)

Department of Hematology, Karolinska University Hospital, Stockholm, Sweden.
Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.

Stephan Mielke (S)

Department of Laboratory Medicine, Biomolecular and Cellular Medicine, Karolinska Institutet, Stockholm, Sweden.
Department of Cellular Therapy and Allogeneic Stem Cell Transplantation (CAST), Karolinska Comprehensive Cancer Center, Karolinska University Hospital Huddinge, Stockholm, Sweden.

Piotr Nowak (P)

Department of Infectious Diseases, Karolinska University Hospital, Stockholm, Sweden.
Department of Medicine Huddinge, Infectious Diseases, Karolinska Institutet, Stockholm, Sweden.
Laboratory for Molecular Infection Medicine Sweden MIMS, Umeå University, Umeå, Sweden.

Jan Vesterbacka (J)

Department of Infectious Diseases, Karolinska University Hospital, Stockholm, Sweden.
Department of Medicine Huddinge, Infectious Diseases, Karolinska Institutet, Stockholm, Sweden.

Mira Akber (M)

Department of Medicine Huddinge, Center for Infectious Medicine, Karolinska Institutet, Stockholm, Sweden.

Anna Olofsson (A)

Division of Clinical Microbiology, Department of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden.

Susana Patricia Amaya Hernandez (SP)

Department of Health Technology, Section of Experimental and Translational Immunology, Technical University of Denmark, Kongens Lyngby, Denmark.

Yu Gao (Y)

Department of Medicine Huddinge, Center for Infectious Medicine, Karolinska Institutet, Stockholm, Sweden.

Curtis Cai (C)

Department of Medicine Huddinge, Center for Infectious Medicine, Karolinska Institutet, Stockholm, Sweden.

Gunnar Söderdahl (G)

Department of Transplantation, Karolinska University Hospital, Stockholm, Sweden.
Department of Clinical Science, Intervention and Technology, Karolinska Institutet, Stockholm, Sweden.

C I Edvard Smith (CIE)

Department of Infectious Diseases, Karolinska University Hospital, Stockholm, Sweden.
Department of Laboratory Medicine, Biomolecular and Cellular Medicine, Karolinska Institutet, Stockholm, Sweden.
Department of Cellular Therapy and Allogeneic Stem Cell Transplantation (CAST), Karolinska Comprehensive Cancer Center, Karolinska University Hospital Huddinge, Stockholm, Sweden.

Anders Österborg (A)

Department of Hematology, Karolinska University Hospital, Stockholm, Sweden.
Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.

Karin Loré (K)

Department of Medicine Solna, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.

Margaret Sällberg Chen (M)

Department of Dental Medicine, Karolinska Institutet, Stockholm, Sweden.

Per Ljungman (P)

Department of Cellular Therapy and Allogeneic Stem Cell Transplantation (CAST), Karolinska Comprehensive Cancer Center, Karolinska University Hospital Huddinge, Stockholm, Sweden.
Department of Medicine Huddinge, Hematology, Karolinska Institutet, Stockholm, Sweden.

Hans-Gustaf Ljunggren (HG)

Department of Medicine Huddinge, Center for Infectious Medicine, Karolinska Institutet, Stockholm, Sweden.

Annika C Karlsson (AC)

Division of Clinical Microbiology, Department of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden.
Karolinska University Laboratory, Clinical Microbiology, Karolinska University Hospital, Stockholm, Sweden.

Sunil Kumar Saini (SK)

Department of Health Technology, Section of Experimental and Translational Immunology, Technical University of Denmark, Kongens Lyngby, Denmark.

Soo Aleman (S)

Department of Infectious Diseases, Karolinska University Hospital, Stockholm, Sweden.
Department of Medicine Huddinge, Infectious Diseases, Karolinska Institutet, Stockholm, Sweden.

Marcus Buggert (M)

Department of Medicine Huddinge, Center for Infectious Medicine, Karolinska Institutet, Stockholm, Sweden.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH